Nothing Special   »   [go: up one dir, main page]

CL2023003605A1 - Conjugados de neodegradador-anticuerpo anti-cd33 - Google Patents

Conjugados de neodegradador-anticuerpo anti-cd33

Info

Publication number
CL2023003605A1
CL2023003605A1 CL2023003605A CL2023003605A CL2023003605A1 CL 2023003605 A1 CL2023003605 A1 CL 2023003605A1 CL 2023003605 A CL2023003605 A CL 2023003605A CL 2023003605 A CL2023003605 A CL 2023003605A CL 2023003605 A1 CL2023003605 A1 CL 2023003605A1
Authority
CL
Chile
Prior art keywords
neodegrader
antibody conjugates
compositions
conjugates
neodegraders
Prior art date
Application number
CL2023003605A
Other languages
English (en)
Inventor
Fishkin Nathan
U Park Peter
Bai Chen
Original Assignee
Bristol Myers Squibb Co
Orum Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Orum Therapeutics Inc filed Critical Bristol Myers Squibb Co
Publication of CL2023003605A1 publication Critical patent/CL2023003605A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona neodegradadores conjugados con anticuerpos anti-CD33. También se proporcionan composiciones que comprenden los conjugados. Los compuestos y composiciones son útiles para tratar una enfermedad o afección, por ejemplo, cáncer, en un sujeto que los necesita.
CL2023003605A 2021-06-03 2023-12-01 Conjugados de neodegradador-anticuerpo anti-cd33 CL2023003605A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163202272P 2021-06-03 2021-06-03
US202163282588P 2021-11-23 2021-11-23

Publications (1)

Publication Number Publication Date
CL2023003605A1 true CL2023003605A1 (es) 2024-05-03

Family

ID=84323935

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003605A CL2023003605A1 (es) 2021-06-03 2023-12-01 Conjugados de neodegradador-anticuerpo anti-cd33

Country Status (12)

Country Link
US (1) US20240252671A1 (es)
EP (1) EP4346910A1 (es)
JP (1) JP2024521919A (es)
KR (1) KR20240042598A (es)
AU (1) AU2022284372A1 (es)
CA (1) CA3222185A1 (es)
CL (1) CL2023003605A1 (es)
CO (1) CO2023016712A2 (es)
IL (1) IL308812A (es)
MX (1) MX2023014282A (es)
TW (1) TW202313022A (es)
WO (1) WO2022254377A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023221975A1 (zh) * 2022-05-18 2023-11-23 苏州宜联生物医药有限公司 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
WO2024169913A1 (zh) * 2023-02-15 2024-08-22 石药集团巨石生物制药有限公司 一种度胺类分子胶衍生物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2358697T3 (pl) * 2008-10-29 2016-04-29 Celgene Corp Związki izoindolinowe do zastosowania w leczeniu raka
IL296846A (en) * 2020-03-31 2022-11-01 Orum Therapeutics Inc Clutches of new joint material

Also Published As

Publication number Publication date
CO2023016712A2 (es) 2024-02-26
AU2022284372A9 (en) 2024-01-11
KR20240042598A (ko) 2024-04-02
TW202313022A (zh) 2023-04-01
IL308812A (en) 2024-01-01
CA3222185A1 (en) 2022-12-08
WO2022254377A1 (en) 2022-12-08
JP2024521919A (ja) 2024-06-04
US20240252671A1 (en) 2024-08-01
MX2023014282A (es) 2024-02-27
EP4346910A1 (en) 2024-04-10
AU2022284372A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
CO2023016712A2 (es) Conjugados de neodegradador-anticuerpo anti-cd33
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
CL2022001030A1 (es) Compuestos moduladores de glp-1r
CL2023003604A1 (es) Conjugados de neodegradadores
CL2021000293A1 (es) Anticuerpos anti-trem2 y métodos relacionados (divisional de solicitud no.202001575)
CL2020001333A1 (es) Moléculas de unión b7-h3 novedosas, conjugados anticuerpo-fármaco de los mismos y métodos de uso de los mismos. (divisional solicitud 201802895)
CO2020000772A2 (es) Conjugado de anticuerpo monoclonal contra bcma -fármaco incorporación por referencia de material presentado electrónicamente
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
CY1118763T1 (el) Αντισωμα αντι-ερηα2
CU23809A3 (es) Anticuerpo específico prlr
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
PE20110797A1 (es) Anticuerpos anti mn
DOP2020000020A (es) Anticuerpos anti-cd137
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
EA202091161A1 (ru) Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CL2023001800A1 (es) Conjugados anticuerpo-fármaco específicos para tumores con claudina 18.2
BR112022008756A2 (pt) Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso
CU20210096A7 (es) Moléculas de unión a cd19
CL2023000741A1 (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos.
CO2024009571A2 (es) Inhibidores de parp1
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CO2023017609A2 (es) Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso
CO2024007192A2 (es) Moléculas de anticuerpo y conjugados